Campbell & CO Investment Adviser LLC Takes Position in Axon Enterprise, Inc $AXON

Campbell & CO Investment Adviser LLC bought a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to its most recent filing with the SEC. The firm bought 3,345 shares of the biotechnology company’s stock, valued at approximately $2,769,000.

Several other large investors also recently bought and sold shares of the stock. Hemington Wealth Management lifted its stake in shares of Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after buying an additional 17 shares during the period. Whipplewood Advisors LLC raised its stake in Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 27 shares during the last quarter. NewSquare Capital LLC lifted its position in Axon Enterprise by 96.2% during the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 25 shares during the period. Washington Trust Advisors Inc. grew its stake in Axon Enterprise by 44.7% during the 2nd quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 17 shares during the last quarter. Finally, TCTC Holdings LLC increased its holdings in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of research reports. Bank of America lifted their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. UBS Group dropped their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Finally, Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $810.71.

Axon Enterprise Stock Performance

AXON opened at $602.51 on Monday. The firm has a fifty day moving average price of $719.61 and a 200 day moving average price of $737.16. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91. The stock has a market cap of $47.54 billion, a P/E ratio of 148.77, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm’s quarterly revenue was up 30.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $713.74, for a total value of $7,137,400.00. Following the completion of the transaction, the chief executive officer owned 3,033,982 shares of the company’s stock, valued at approximately $2,165,474,312.68. This represents a 0.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer directly owned 93,592 shares in the company, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,932 shares of company stock worth $36,802,716 over the last quarter. Company insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.